Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 5
2004 5
2005 12
2006 10
2007 12
2008 13
2009 16
2010 27
2011 27
2012 32
2013 29
2014 30
2015 32
2016 26
2017 41
2018 37
2019 33
2020 52
2021 46
2022 37
2023 34
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

505 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Ferraro A, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani R, McAlear C, Moreland LW, Mynard K, Nachman P, Pagnoux C, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Wroe C, Jayne D, Merkel PA; RITAZAREM co-investigators. Smith RM, et al. Among authors: jones rb. Ann Rheum Dis. 2023 Jul;82(7):937-944. doi: 10.1136/ard-2022-223559. Epub 2023 Mar 23. Ann Rheum Dis. 2023. PMID: 36958796 Free PMC article. Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Jones RB, et al. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169. N Engl J Med. 2010. PMID: 20647198 Free article. Clinical Trial.
Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
Benichou N, Charles P, Terrier B, Jones RB, Hiemstra T, Mouthon L, Bajema I, Berden A, Thervet E, Guillevin L, Jayne D, Karras A; French Vasculitis Study Group (FVSG) and European Vasculitis Society (EUVAS) investigators. Benichou N, et al. Among authors: jones rb. Kidney Int. 2023 Jun;103(6):1144-1155. doi: 10.1016/j.kint.2023.02.029. Epub 2023 Mar 20. Kidney Int. 2023. PMID: 36940799 Clinical Trial.
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani RA, Makino H, McAlear CA, Monach P, Moreland LW, Mynard K, Nachman P, Pagnoux C, Pearce F, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Weisman MH, Wroe C, Merkel PA, Jayne D; RITAZAREM coinvestigators; RITAZAREM co-investigators. Smith RM, et al. Among authors: jones rb. Ann Rheum Dis. 2020 Sep;79(9):1243-1249. doi: 10.1136/annrheumdis-2019-216863. Epub 2020 Jun 24. Ann Rheum Dis. 2020. PMID: 32581088 Free PMC article.
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR; European Vasculitis Society (EUVAS). Jones RB, et al. Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404. Epub 2015 Mar 4. Ann Rheum Dis. 2015. PMID: 25739829 Clinical Trial.
Maternal and Newborn Hospital Outcomes of Perinatal SARS-CoV-2 Infection: A National Registry.
Hudak ML, Flannery DD, Barnette K, Getzlaff T, Gautam S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Ellington SR, Galang RR, Snead MC, Woodworth KR, Zapata LB, Puopolo KM; AMERICAN ACADEMY OF PEDIATRICS NPC-19 REGISTRY INVESTIGATORS. Hudak ML, et al. Pediatrics. 2023 Feb 1;151(2):e2022059595. doi: 10.1542/peds.2022-059595. Pediatrics. 2023. PMID: 36995183
Spirooxindoles as Potential Pharmacophores.
Panda SS, Jones RA, Bachawala P, Mohapatra PP. Panda SS, et al. Among authors: jones ra. Mini Rev Med Chem. 2017;17(16):1515-1536. doi: 10.2174/1389557516666160624125108. Mini Rev Med Chem. 2017. PMID: 29056096 Review.
505 results